|
| 36318705 | Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA. | Clin Cancer Res | 2023 |
| 37555284 | Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399. | Oncologist | 2023 |
| 38064163 | The ENGAGE study: evaluation of a conversational virtual agent that provides tailored pre-test genetic education to cancer patients. | J Cancer Surviv | 2023 |
| 37637935 | A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors. | Cancer Res Commun | 2023 |
| 37422371 | Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE). | Eur Urol Focus | 2023 |
| 37455214 | Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808. | Clin Genitourin Cancer | 2023 |
| 37018918 | Flashback Foreword: Pazopanib in Renal Cell Carcinoma and Overall Survival With Sunitinib Versus Interferon-α in Metastatic Renal Cell Carcinoma. | J Clin Oncol | 2023 |
| 37040594 | External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. | J Clin Oncol | 2023 |
| 36857796 | Role of bromodomain and extraterminal (BET) proteins in prostate cancer. | Expert Opin Investig Drugs | 2023 |
| 36540051 | Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT study. | Cancer Med | 2023 |
| 36367998 | Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial. | J Clin Oncol | 2023 |
| 35133567 | A PRO-cision medicine intervention to personalize cancer care using patient-reported outcomes: intervention development and feasibility-testing. | Qual Life Res | 2022 |
| 35439030 | Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers? | J Clin Oncol | 2022 |
| 35377734 | Oncologist Peer Comparisons as a Behavioral Science Strategy to Improve Hospice Utilization. | JCO Oncol Pract | 2022 |
| 35538398 | Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805. | Prostate | 2022 |
| 35598359 | Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study. | Eur J Cancer | 2022 |
| 35816286 | Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer. | Clin Cancer Res | 2022 |
| 36328377 | FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy. | J Immunother Cancer | 2022 |
| 35985981 | Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4:543-52]. | Eur Urol Oncol | 2022 |
| 36087093 | Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer. | Mol Oncol | 2022 |
| 36085183 | Physicians' use of plain language during discussions of prostate cancer clinical trials with patients. | Patient Educ Couns | 2022 |
| 35013522 | Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics. | Prostate Cancer Prostatic Dis | 2022 |
| 32536574 | Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer. | Eur Urol Oncol | 2021 |
| 37364021 | Development and pilot test of a physician-focused cancer clinical trials communication training intervention. | PEC Innov | 2021 |
| 33823432 | High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic review. | Cancer Treat Rev | 2021 |
| 33707112 | Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma. | Eur Urol | 2021 |
| 33617303 | TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. | J Clin Oncol | 2021 |
| 33755233 | What are survivorship care plans failing to tell men after prostate cancer treatment? | Prostate | 2021 |
| 33636027 | Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial. | Prostate | 2021 |
| 33884414 | Effects of Behavioral Weight Loss and Metformin on IGFs in Cancer Survivors: A Randomized Trial. | J Clin Endocrinol Metab | 2021 |
| 34645612 | Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer. | Cancer Res | 2021 |
| 34020931 | Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503). | Eur Urol Oncol | 2021 |
| 34129855 | Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial. | Ann Oncol | 2021 |
| 34064995 | Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology. | Cancers (Basel) | 2021 |
| 34337548 | Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. | Eur Urol Open Sci | 2021 |
| 33477113 | End-of-Life Characteristics Associated With Short Hospice Length of Stay for Patients With Solid Tumors Enrolled in Phase I Clinical Trials. | J Natl Compr Canc Netw | 2021 |
| 33048621 | Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat? | J Clin Oncol | 2021 |
| 33419682 | The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. | Eur Urol | 2021 |
| 33383350 | Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy. | Eur J Cancer | 2021 |
| 33121909 | Changes in the place of death for older adults with cancer: Reason to celebrate or a risk for unintended disparities? | J Geriatr Oncol | 2021 |
| 32798608 | Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer. | Int J Radiat Oncol Biol Phys | 2021 |
| 32624280 | A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. | Eur Urol | 2021 |
| 31176623 | Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer. | Eur Urol | 2020 |
| 31790330 | Unpacking Trial Offers and Low Accrual Rates: A Qualitative Analysis of Clinic Visits With Physicians and Patients Potentially Eligible for a Prostate Cancer Clinical Trial. | JCO Oncol Pract | 2020 |
| 31702432 | Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma. | J Urol | 2020 |
| 32053149 | HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer. | JAMA Oncol | 2020 |
| 33004542 | Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer. | J Immunother Cancer | 2020 |
| 32807727 | Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial. | Eur Urol Oncol | 2020 |
| 32940630 | Willingness to Discuss Clinical Trials Among Black vs White Men With Prostate Cancer. | JAMA Oncol | 2020 |
| 32903246 | Problem Solving to Enhance Clinical Trial Participation Utilizing a Framework-Driven Approach. | Clin Adv Hematol Oncol | 2020 |